Anupam Rasayan Acquires US Firm Jayhawk Fine Chemicals for $150M
Anupam Rasayan acquired US-based Jayhawk Fine Chemicals for $150 million on Dec 9, 2025. The deal strengthens ARIL's global CDMO platform and provides US manufacturing presence. Combined pro-forma revenues are ~$243M with ~$61M EBITDA. Jayhawk reported $78M revenue in CY24 with 19% EBITDA margins. ARIL invested $40M, with $110M from a global investment firm.
The acquisition is significant, providing direct US manufacturing presence, expanding the product portfolio into high-growth sectors, and enhancing the company's integrated supply chain capabilities.
The acquisition is strategic, aligns with the company's long-term goals, is expected to be EPS-accretive, and strengthens the company's global footprint and market position.
Anupam Rasayan India Limited (ARIL) has announced the acquisition of 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals company, from the CABB Group. The definitive agreement was signed on December 9, 2025. Jayhawk, headquartered in Kansas, USA, is a specialized manufacturer with capabilities in custom manufacturing, high-quality processing, and complex chemical synthesis.
This acquisition aligns with ARIL's strategy to build a global integrated specialty and CDMO platform. It provides ARIL with a direct onshore manufacturing presence in the United States, enhancing engagement with multinational customers who value geographic diversification and supply chain resilience. The acquisition also strengthens ARIL's platform by adding advanced intermediates and N-1 molecules for high-performance materials and life-science customers, complementing its existing backward integration in fluorination raw materials through its investment in Tanfac.
The acquired portfolio includes high-value di-anhydrides and polyimide intermediates, positioning ARIL as a strong integrated player in the semiconductor, automotive, EV, aviation, and electronics sectors. The transaction is expected to be EPS-accretive from day one. On a pro-forma basis, the combined entity would have revenues of approximately USD 243 million and an EBITDA of approximately USD 61 million.
The enterprise value of the acquisition is approximately USD 134 million, implying an EBITDA multiple of around 9x CY'24 earnings. The total purchase consideration is approximately USD 150 million, including USD 16 million in cash on Jayhawk's balance sheet. ARIL will invest USD 40 million through internal accruals and debt, while a leading global investment management firm will invest approximately USD 110 million in Class B non-voting shares, allowing ARIL to fully consolidate Jayhawk's financials. Jayhawk reported approximately USD 78 million in revenue in CY24 with EBITDA margins of around 19%, with 65% of revenue from performance materials and the rest from life and life science-related molecules.
The transcript of the investor call held on December 15, 2025, discussing the US acquisition update, was submitted to the stock exchanges on December 19, 2025. The company's website also hosts this information.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.